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Cutaneous melanoma arises from the malignant transformation of skin melanocytes; its
incidence and mortality have been increasing steadily over the last 50 years, now rep-
resenting 3% of total tumors. Once melanoma metastasizes, prognosis is somber and
therapeutic options are limited. However, the discovery of prevalent BRAF mutations in at
least 50% of melanoma tumors led to development of BRAF-inhibitors, and other drugs tar-
geting the MAPK pathway including MEK-inhibitors, are changing this reality.These recently
approved treatments for metastatic melanoma have made a significant impact on patient
survival; though the results are shadowed by the appearance of drug-resistance. Combi-
nation therapies provide a rational strategy to potentiate efficacy and potentially overcome
resistance. Undoubtedly, the last decade has also born a renaissance of immunotherapy,
and encouraging advances in metastatic melanoma treatment are illuminating the road.
Immune checkpoint blockades, such as CTLA-4 antagonist-antibodies, and multiple can-
cer vaccines are now invaluable arms of anti-tumor therapy. Recent work has brought
to light the delicate relationship between tumor biology and the immune system. Host
immunity contributes to the anti-tumor activity of oncogene-targeted inhibitors within a
complex network of cytokines and chemokines.Therefore, combining immunotherapy with
oncogene-targeted drugs may be the key to melanoma control. Here, we review ongoing
clinical studies of combination therapies using both oncogene inhibitors and immunothera-
peutic strategies in melanoma patients. We will revisit the preclinical evidence that tested
sequential and concurrent schemes in suitable animal models and formed the basis for the
current trials. Finally, we will discuss potential future directions of the field.
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INTRODUCTION
The American Cancer Society projected 76,100 new cases of
melanoma in the United States in 2014 (1). These cases represent
<2% of total skin cancer diagnoses,but account for an overwhelm-
ing proportion of skin cancer deaths. Melanoma incidence has
been increasing for at least 30 years, and between 2006 and 2010
the incidence rate among Caucasians increased by 2.7% per year.
Though incidence is rising, mortality has been declining rapidly in
Caucasians under 50: from 2006 to 2010, mortality rates decreased
by 2.6% per year in men and by 2.0% per year in women. In con-
trast, among Caucasians 50 and older, mortality increased by 1.1%
per year in men and by 0.2% per year in women during this same
time period. Even with this decline in mortality, the American
Cancer Society predicted 9,710 deaths from melanoma in 2014 (1).
Standard cutaneous melanoma (CM) treatment consists of sur-
gical removal of the primary tumor and surrounding normal
Abbreviations: ACT, adoptive cell therapy; AE, adverse events; Ag, antigen/s; APC,
antigen-presenting cells; CM, cutaneous melanoma; CR, complete response; DC,
dendritic cells; DFS, disease-free survival; EMEA, European Medicines Agency;
FDA, Federal Drug Administration; HD IL-2, high-dose interleukin-2; IFA, incom-
plete Freund’s adjuvant; irAEs, immune-related adverse events; mAbs, monoclonal
antibodies; ORR, overall response rate; OS, overall survival; PFS, progression-free
survival; RTK, receptor tyrosine kinase; TIL, tumor infiltrating lymphocytes.
tissue; a sentinel lymph node is routinely biopsied to deter-
mine stage (2). More extensive surgery may be needed if the
lymph nodes are compromised. Melanomas with deep local inva-
sion, or that have spread to the lymph nodes, may be treated
with surgery, immunotherapy, chemotherapy, and/or radiation
therapy. Advanced cases may be treated with palliative surgery,
chemotherapy and/or radiation therapy, and newer targeted or
immunotherapy drugs.
Melanoma is highly curable if detected in its earliest stages and
treated properly (1, 2). However, melanoma is likely to spread to
other parts of the body. The 5- and 10-year relative survival rates
for melanoma patients are 91 and 89%, respectively. For local-
ized melanoma (84% of cases), the 5-year survival rate is 98%;
survival declines to 62 and 16% for regional and distant stage
disease, respectively. Patients with tumors that have invaded the
deep dermis or spread to the draining lymph nodes have a high
risk of recurrence after surgery, and safe and effective therapeu-
tic options are still limited as adjuvant treatments. The approval
of oncogene-targeted drugs such as vemurafenib and dabrafenib
for BRAFV600 mutated melanoma (3, 4), and of monoclonal anti-
bodies (mAbs) targeting immunomodulatory molecules such as
ipilimumab for CTLA-4 (5) and pembrolizumab for PD-1 (6),
has dramatically changed the treatment of advanced melanoma
in recent years. All of these agents have demonstrated a positive
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impact on overall survival (OS) and impressive clinical responses
in advanced melanoma patients. However, related toxicity and
emerging resistance are ongoing challenges. There is increasing
evidence that a combination therapy using oncogene-targeted
drugs and immunotherapy could produce long-lasting responses
in a broader spectrum of patients.
In the present work, we will revisit the latest, promis-
ing oncogene-targeted drugs and several immunotherapeutic
approaches that are under intense research, as well as their clini-
cal effects on melanoma patients. We will discuss the preclinical
and clinical evidence supporting the rationale for the combination
of oncogene-targeted therapies and immunotherapy to improve
patient outcome.
ADVANCES IN MELANOMA TREATMENT
ONCOGENE-TARGETED DRUGS
Cutaneous melanoma has the highest mutational frequency of
any tumor pathology. Tumor transformation and progression
is believed to be sustained by the emergent combination of
genetic changes (7). Whole-genome sequencing studies reveal that
the point mutation load is proportional to UV exposure rays
(C>T/G>A), with the highest rates in patients with a doc-
umented history of chronic sun exposure; however, there are
also non-related sun exposure mutations (8). A recent report
describing a panel of cancer mutations in clinical melanoma sam-
ples of different subtypes, including cutaneous, acral, mucosal,
and unknown primary melanomas, revealed that the number of
mutations per tumor was associated with melanoma subtype (9).
Here, we will describe the most prevalent mutations in melanoma
that resulted in development of targeted therapies, some with
impressive clinical results.
The canonical MAPK signaling pathway – receptor tyrosine
kinase (RTK)–RAS–RAF–MEK–ERK – promotes survival, growth,
migration, and resistance to apoptosis. The MAPK pathway ini-
tiates in the cell membrane, either by ligand interaction with a
RTK, or by the adhesion of integrins to the extracellular matrix.
Mutations in the serine/threonine–protein kinase BRAF were
identified a decade ago as the most frequent in CM, with a
prevalence of ~40–60% clinical cases (10). Updated data reveal
that the T1799A mutation, resulting in the BRAFV600E consti-
tutively active isoform, accounts for ~75% of BRAFV600 gene
mutations (11). Other less frequent variants include BRAFV600K
and BRAFV600R, which are present in ~20 and ~4% of BRAFV600
cases. In melanoma, NRAS mutations are rare in BRAFV600
tumors (1.6%). Among 20% of melanoma tumors are mutated
in NRAS, especially in exon 2 (NRASQ61R/Q61K/Q61L). Addition-
ally, 16% of melanoma tumors present TP53 mutations, and
concurrent TP53 mutations are the most frequent events in
tumors with BRAFV600 or NRAS mutations. BRAFV600 and TP53
mutations are significantly associated with cutaneous primary
tumor location, while NRAS and c-KIT alterations were associ-
ated with acral and mucosal melanoma (9). Other sequencing
studies indicate that 8% of MEK1 and MEK2 mutations may
occur simultaneously with BRAF (60%) or NRAS (10%) muta-
tions (12). The most frequent MEK mutants, MEK1P124S and
MEK1E203K, are related to ERK phosphorylation. All of these dri-
ver mutations lead to the constitutive activation of the MAPK
pathway; thus, they arose as appropriate druggable targets with
specific inhibitors.
Vemurafenib (PLX-4032, Zelboraf, Roche) is a small, orally
bioavailable molecule that selectively binds the ATP-binding site
of BRAFV600E kinase and inhibits its activity (13). Vemurafenib
efficacy was assessed in a randomized clinical trial against Dacar-
bazine in metastatic CM patients carrying the BRAFV600E muta-
tion. Vemurafenib produced a higher response rate (48 vs. 5%),
and an increase in OS (84 vs. 64%) and disease-free survival (DFS)
(5.3 vs. 1.6 months). Impressive rapid tumor remissions were
observed,with a median time-to-response of 1.45 months (3). Skin
complications were frequently associated with treatment: 24% of
patients from the vemurafenib arm developed low-grade cuta-
neous squamous-cell carcinomas or keratoacanthomas, through
paradoxical ERK activation. These tumors required excision and
continuous dermatologic evaluation during treatment. Fortu-
nately, patients with BRAFV600 mutations other than BRAFV600E
will respond to vemurafenib, including BRAFV600K and BRAFV600R
(14, 15). Vemurafenib became one of the cornerstones of metasta-
tic or unresectable CM treatment with its approval in 2011 by the
Federal Drug Administration (FDA) and in 2012 by the European
Medicines Agency (EMEA). Despite the impressive initial tumor
remissions observed with vemurafenib, drug-resistance has lim-
ited the duration of remissions; therefore, great efforts are being
directed toward revealing and overcoming the mechanisms of
resistance to BRAF inhibition (16).
Dabrafenib (Tafinlar, GlaxoSmithKline) is another orally
bioavailable BRAFV600E small-molecule inhibitor, which was
approved by the FDA and EMEA in 2013 for treatment of unre-
sectable or metastatic CM with BRAFV600E mutation. In a random-
ized trial of advanced CM patients with BRAFV600E determined
tumors, dabrafenib significantly improved progression-free sur-
vival (PFS) compared to Dacarbazine (5.1 vs. 2.7 months) (4).
Although 6% of patients from the dabrafenib arm developed
keratoacanthoma or squamous-cell skin carcinoma, they did not
require dose modification or interruption. Trametinib (Mekinist,
GlaxoSmithKline) is an oral MEK1 and MEK2 inhibitor targeting
the MAPK pathway downstream. This inhibitor provided longer
PFS than Dacarbazine and Paclitaxel (4.8 vs. 1.5 months) for CM
patients with unresectable metastatic BRAFV600E tumors, and was
therefore approved for CM treatment by the FDA in 2013, and
by the EMEA in 2014 (17). The combination of dabrafenib and
trametinib proved superior to monotherapy and produced fewer
side effects, which led to FDA approval in January 2014.
Upstream in the MAPK pathway, there are altered RTKs
in melanoma, including c-KIT, EGFR, and PDGFR. c-KIT is
involved in the development and maintenance of melanocytes,
activating the MAPK, PI3K–AKT, and Janus kinases (JAK)–signal
transducers and activators of transcription (STAT) prolifera-
tion and survival pathways. Amplifications or mutations in c-
KIT account for 4% of melanomas, and are most frequently
found in acral, mucosal, and chronically sun-damaged skin (18).
Although less prevalent in Caucasian populations, these sub-
types constitute approximately 65% of the melanomas observed
in Asians and African American populations. A large mutational
analysis of RTKs performed in metastatic CM samples revealed
that growth factor receptor ERBB4 was mutated in 19% of the
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samples. This receptor is involved in AKT signaling, and can be
down-regulated by either ERBB4 knockdown or inhibition with
Lapatinib (19).
Imatinib (Gleevec, Novartis) is an orally available, chemical
ATP-competitive RTK inhibitor, which prevents phosphorylation
and the subsequent activation of growth receptors and their
downstream signal transduction pathways. Its efficacy was ini-
tially demonstrated in the BCR-ABL oncogene in hematological
malignancies, and in RTKs such as c-KIT and PDGFR, which are
frequently altered in gastrointestinal tumors. A phase II study in
metastatic melanoma patients with mutated or amplified c-KIT
showed a 23% overall response rate (ORR) with imatinib therapy
(20). Dasatinib (Sprycel, Bristol-Myers Squibb) is another syn-
thetic broad-spectrum multi-kinase inhibitor, with potent effect
on BCR-ABL, SRC, c-KIT, PDGFR, and ephrin TK. Dasatinib has
demonstrated only modest clinical efficacy in melanoma patients
as a single agent (21). Tumor regression was noted in approxi-
mately 14% of total patients without c-kit mutations, and in one
of two patients with tumor c-kit mutations. This level of activity
suggests that biomarker-based patient pre-selection, in this case
by c-KIT alteration, may identify a subset of patients that can
potentially derive benefit from dasatinib.
MONOCLONAL ANTIBODIES
Tumor evolution is the result of continuous feedback between
tumor cells and their environment. The immune system is a cru-
cial player, since it can both repress and enable tumor growth and
is capable of shifting from an anti-tumor immune environment
to a tumor-permissive one, as described by the theory of cancer
immunoediting (22). There is significant evidence of molecules
and immune populations involved in tumor immunoediting in
CM (23). In particular, immune checkpoints refer to the circuit of
inhibitory pathways that the immune system uses to modulate the
duration and amplitude of immune responses. Many of these sig-
nals are initiated by ligand–receptor interactions and many tumors
express these ligands as a mechanism of immune escape, particu-
larly against tumor specific T cells. However, these ligand–receptor
interactions can be blocked by specific antibodies, which then halt
the immune checkpoint blockade and favor an effector anti-tumor
immune response. The binding of co-stimulatory B7 molecules in
Antigen-Presenting Cells (APC) to the CD28 receptor on naïve T
cells induces the expression of CTLA-4 (cytotoxic T-lymphocyte-
associated antigen-4). The CTLA-4 molecule has a higher affinity
for B7 than CD28 and has an inhibitory function, thereby help-
ing to extinguish the signal. Another inhibitory molecule is PD-1
(Programed death-1), which is a co-receptor expressed in activated
and exhausted T and B cells. Activated PD-1 negatively regulates T
cell activation through the suppression of the PI3K/Akt pathway.
PD-1 interacts with two ligands: B7-H1 (PD-L1), the main medi-
ator of the immunosuppressive response, and B7-H2 (PD-L2). In
tumor pathology, PD-L1 expression is increased on tumor cells
and APCs, while the expression of CTLA-4 is increased on APCs
and effector T cells (24, 25).
Ipilimumab (Yervoy, Bristol-Myers Squibb) is a monoclonal
antibody (IgG1) directed against CTLA-4 that was developed
for systemic anti-tumor immunotherapy. The effects of ipili-
mumab in unresectable melanoma patients were assessed in a
randomized trial against a gp100-peptide vaccine. Patients receiv-
ing ipilimumab plus gp100-peptide vaccine showed improved
OS in comparison to those receiving the vaccine alone (10.1 vs.
6.4 months), with a median time-to-response of 3.3 months. ORR
after ipilimumab administration ranged from 10 to 20%. Fur-
thermore, complete regression continued throughout the 2 years
of follow-up. No differences in OS were observed between ipili-
mumab treatment alone and ipilimumab plus the gp100-peptide
vaccine (5). Because ipilimumab stimulates T cells, there is sub-
stantial risk of immune-related adverse events (irAEs). In this
trial, 10–15% of patients presented grade 3/4 irAEs, with seven
related deaths. Management of irAEs included initiation of high-
dose corticosteroids and discontinuation of ipilimumab. In 2011,
the FDA and EMEA approved the use of ipilimumab for the
treatment of unresectable or metastatic melanoma, contribut-
ing to the renaissance of immunotherapy in cancer treatment.
Given the potential for toxicity, ipilimumab approval was predi-
cated on a risk evaluation and mitigation strategy. Tremelimumab
(CP-675206, Pfizer/MedImmune) is another recently developed
CTLA-4-blocking monoclonal antibody (IgG2). Although treme-
limumab generated durable responses in metastatic melanoma
patients in phase I and II trials, it failed to demonstrate a sur-
vival advantage in a randomized trial against standard-of-care
chemotherapy (26).
Pembrolizumab (formerly Lambrolizumab, Keytruda, Merck),
an IgG4 monoclonal antibody against PD-1, was recently approved
in September 2014 by the FDA for treatment of patients with
unresectable or metastatic melanoma. Approval was based on the
results obtained in a randomized trial comparing two doses of
pembrolizumab in metastatic melanoma patients whose cancer
had progressed following treatment with ipilimumab or targeted
therapy in BRAFV600 tumors (NCT01295827) (6). Key exclusion-
ary criteria included any autoimmune disease, induced immuno-
suppression, and/or a history of severe irAEs from treatment with
ipilimumab. The ORR was 26% at both doses, with a median time-
to-response of 12 months. Treatment was well tolerated; the only
drug-related grade 3 adverse event was fatigue, which was reported
by 3% of patients in the 2 mg/kg pembrolizumab group. Cur-
rently, there are two ongoing, randomized, confirmatory trials for
pembrolizumab in advanced melanoma patients (NCT01866319,
NCT02083484). Nivolumab (Bristol-Myers Squibb) is another
antagonist monoclonal antibody (IgG4) specific to PD-1. A phase
I trial in several solid tumors showed a cumulative response in 28%
of melanoma patients (27). Interestingly, only patients with PD-
L1-positive tumors achieved an objective response, suggesting a
relationship between PD-L1 expression on tumor cells and clinical
response. Only one patient experienced a serious AE, inflamma-
tory colitis. Controlled phase III trials of nivolumab vs. standard-
of-care chemotherapy with prospective survival end points are
currently underway (NCT01721772, NCT01721746) in melanoma
patients. In a phase I trial in metastatic melanoma patients,
co-administration of nivolumab and ipilimumab, followed by
nivolumab, resulted in rapid ORR in 40% of patients, with an
acceptable level of AEs (28). Currently, a phase III study comparing
nivolumab or nivolumab plus ipilimumab vs. ipilimumab alone in
advanced melanoma patients is underway (NCT01844505). Fur-
thermore, specific biomarkers are being studied, including baseline
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variations in activated and memory T cells, interferon inducible
factors, and tumor T cell infiltration (CD4+ and CD8+ cells)
(NCT01621490).
Another strategy for interference with the PD-1↔PD-L1 axis
is BMS-936559 (Bristol-Myers Squibb), a monoclonal antibody
(IgG4) targeting PD-L1. In the initial trial, BMS-936559 induced
tumor regression (ORR of 6–17%) and disease stabilization (rates
of 12–41% at 24 weeks) in patients with advanced cancers, includ-
ing non-small-cell lung cancer, melanoma, and renal cancer (29).
Serious AEs were detected in 9% patients. Other antagonist
mAbs against PD-L1 are currently being assessed in clinical tri-
als for metastatic treatment, such as MEDI4736 (Astrazeneca,
NCT01693562) and RG7446 (Roche, NCT01375842).
THERAPEUTIC VACCINES
Cutaneous melanoma is an immunogenic tumor; several tumor
antigens (Ags) have been identified and evidence of tumor immu-
noediting has been observed in patients (23). Immunotherapy has
emerged as an option of interest for CM treatment. Immunother-
apy seeks to stimulate, restore, manage, and even complement the
patient’s own immune system to control tumor growth and dis-
semination. Among other immunotherapeutic approaches, vac-
cines could be administered as an adjuvant therapy after tumor
excision, with the purpose of eliciting long-lasting immunity and
controlling micro-metastatic foci. The rational basis for such vac-
cines is that tumor Ags must be captured by APCs, which migrate
to the lymph nodes where they further activate CD4+ and CD8+
cells. This triggering of the adaptive immune response would also
result in the development of immunological memory. The main
objectives of active immunotherapy against melanoma are to over-
come the immunosuppression produced by the tumor and its
microenvironment, to stimulate specific immune effectors that
can destroy tumor cells, and to increase immunogenicity to tumor
Ag. Pre-existing anti-tumor T cells may be ineffective at reject-
ing the tumor either because their frequency is too low, because
tumor cells were selected to escape recognition, or because such
lymphocytes are functionally deficient. Vaccination can induce
cytokine cascades both locally and systemically, resulting in the
activation and proliferation of anti-melanoma Ag precursors, and
infiltration of effector immune populations into tumors. In gen-
eral, vaccines require two critical components, the Ag source and
the adjuvant (30). Therapeutic vaccines include the use of differ-
ent Ag sources, such as peptides, proteins, nucleic acids, tumor
lysates, recombinant virus, or whole irradiated cells. Alternatively,
dendritic cell (DC) vaccines are comprised of patients’ DC in vitro
loaded with an Ag source, ex vivo matured and then given back to
the patient.
Peptide vaccines are directed at one or several representa-
tive CM Ag. To induce T cell responses, it is necessary to
immunize with adjuvants or Toll-like receptor (TLR) ligands.
Numerous clinical trials were conducted with this strategy, and
although some encouraging results were observed, peptide vac-
cines promote the selection of tumor Ag-negative resistant popu-
lations. Peptide Ags emulsified in incomplete Freund’s adjuvant
(IFA) are widely used to vaccinate cancer patients. While sev-
eral clinical trials testing peptide/IFA-based vaccines have doc-
umented an increase in circulating Ag-specific T cells, objective
therapeutic benefits are rare (31, 32). This may be due to the
presence of large peptide deposits that are protected from degra-
dation and can prime robust specific CD8+ T cell responses,
which are detectable in circulation but not within tumor lesions.
Thus, Ag persistence at the vaccination site can create a T
cell graveyard in which specific T cells accumulate and com-
pete with the tumor site (33). It is clear that other adjuvants
need to be evaluated to improve peptide delivery and immune
cell stimulation.
Therapeutic vaccines comprised of whole cells or cell lysates
allow the immune system to interact with a broad antigenic
repertoire. This is an important consideration, since tumors
are heterogeneous and CM is not an exception (34). A meta-
analysis combining results from 173 immunotherapy clinical trials
of several cancers found that patients immunized with whole-
tumor Ag, including irradiated tumor cells, modified tumor
cells, tumor extracts, tumor mRNAs, and DC pulsed with tumor
extracts, showed an 8.1% clinical response compared with 3.6%
in patients immunized with synthetic or recombinant peptides
and proteins (35). Whole-cell vaccines are still in clinical tri-
als. The GVAX vaccine (36), consisting of irradiated genetically
modified cell lines that secrete granulocyte–macrophage colony
stimulating factor (GM-CSF, Molgramostim), is currently being
assayed in stage IIB-IV melanoma patients in a phase I study
(NCT01435499). We have tested a vaccine comprised of allo-
geneic irradiated CM cells (VACCIMEL) plus BCG as an adju-
vant, combined with i.d. injection of GM-CSF to promote the
local attraction of monocytes and their subsequent differen-
tiation into DC. In the Phase I study, VACCIMEL shown to
be safe, and with a maximum follow-up of 139 months, mean
DFS and OS have not yet been reached for stage II/III vac-
cinated patients (DFS and OS 58.3%) (José Mordoh, personal
communication 2014); all stage IV patients progressed (37).
Currently, the CSF-470 vaccine, which adds a fourth irradiated
melanoma cell line to the VACCIMEL formulation, is being
tested with BCG and GM-CSF against medium dose IFN-alpha
2b in a Phase II–III clinical trial in stage IIB, IIC, and III CM
patients (NCT01729663).
Dendritic cell-vaccines consist of autologous treatments, in
which DC precursors are purified from patients and are loaded
in vitro with tumor Ag (irradiated cells), matured ex vivo, and
then re-infused into the patient (38). In 2010, the FDA approved
Sipuleucel-T, the first DC-based vaccine for the treatment of
metastatic castrate resistant, hormone refractory prostate cancer
(39). Sipuleucel-T (Provenge) is made of an autologous DC-
vaccine preparation loaded with Prostatic acid phosphatase Ag and
GM-CSF. In the case of CM, a phase I–II trial was conducted for
stage IV patients in which autologous DC were pulsed with cocktail
of synthetic five melanoma-associated peptides (gp100, tyrosinase,
MAGE-A2, MAGE-A3, and MART-1 or MAGE-A1) restricted
to HLA-A2 or HLA-A24, and KLH as adjuvant (40). Clinical
responses were observed and OS increased: 13.6 vs. 7.3 months
(vaccinated vs. non-vaccinated), and 21.9 vs. 8.1 months (high
vs. low ELISPOT). Additionally, the presence of the MAGE-A1
auto-antibody before vaccination was determined as a positive
prognostic factor. Other clinical studies have used autologous DC
loaded with peptides, tumor cell lysates (41), killed melanoma cells
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(42), or tumor Ag mRNA electroporation (43), but overall clinical
responses remained disappointingly low. However, the induction
of specific immune responses to tumor Ags has been described.
Several years ago, we demonstrated that autologous DC can cap-
ture apoptotic-necrotic, gamma-irradiated, allogeneic melanoma
cells, inducing the maturation and subsequent migration of DC in
response to the lymph node homing CCL19 chemokine, both in a
murine model (44) and with DC isolated from peripheral blood
monocytes from healthy donors (45). We conducted a Phase I
clinical trial for 16 CM patients. In that study, we observed gp100
and MART-1 specific CD8+T lymphocytes through ELISPOT
and tetramer analysis in five HLA-A*0201 patients before and
after vaccination (46). In an updated analysis with a maximum
follow-up of 132 months, 88.9% stage II–III patients still show
no evidence of melanoma recurrence (José Mordoh, personal
communication 2014).
Dendritic cell-based vaccine design has been variable, it is
difficult to assess the best inoculation site, the optimal num-
ber of DCs to elicit effective immune responses, the Ag-loading
strategies and how to monitor immune effector recruitment in
the tumor microenvironment. A recent review indicated that
DC-based cancer vaccines can elicit adaptive and innate anti-
tumor immunity in at least half of all patients; however, clini-
cal responses remain disappointingly scarce (47). The observed
dissociation between clinical objective response and the prolon-
gation of OS in some patients indicates that alternative surro-
gate endpoints should be used to assess the therapeutic effec-
tiveness of DC-based immunotherapy. DC-based vaccines can
positively affect the clinical outcome in the form of increased
patient survival rather than the induction of tumor objective
responses. The clinical benefit of DC-based immunotherapy is
real but small. With 8.5% of melanoma patients achieving an
objective response, DC therapy has comparable efficacy to Dacar-
bazine, the standard-of-care chemotherapy, and to ipilimumab,
to which 5–15% of patients have an objective response (47).
Today, there are no surrogate markers indicative of relevant anti-
tumor immunization to evaluate vaccine efficacy, meaning that
DFS and OS are the parameters that define vaccine success. Fur-
thermore, there are no predictive markers indicating anti-tumor
immune competence that could identify the patients most likely
to benefit (47).
ADOPTIVE CELL THERAPY
Adoptive Cell Therapy involves the administration of autologous
ex vivo-expanded tumor-reactive T lymphocytes to properly pre-
conditioned recipients. T lymphocytes can be expanded from
tumor infiltrating lymphocytes (TIL) ex vivo from a patient’s
own metastasis after IL-2 and anti-CD3 antibody stimulation. The
expanded T cells are then re-administered after chemotherapy-
induced lymphodepletion of the patient. Such melanoma TILs
recognize their autologous tumor in >75% of patients. Although
adoptive cell therapy (ACT) is typically administered only once,
clinical responses can endure for years. The largest published
description of ACT with significant follow-up showed an ORR of
56% in 93 patients who had followed a variety of lymphodepleting
regimens, 19 patients (21%) had ongoing complete responses (CR)
at 5–9 years of follow-up (48). Other investigators have published
their experiences with ACT and reported a preliminary ORR of
approximately 50%, including some CR (49–51).
OTHER IMMUNOTHERAPIES
The first immunotherapeutic drug approved for treatment
of metastatic melanoma was recombinant Interleukin-2 or
aldesleukin (Proleukin, Prometheus Laboratories), which pro-
motes activation of T, B, and NK-cells. Studies indicate that high
doses of IL-2 (HD IL-2) induced long-term responses in 16% of
patients and a CR in 6% of cases (52). IL-2 provided the first
“proof of principle” that a drug targeting the immune system can
control melanoma at long-term. However, HD IL-2 is very toxic.
Serious AEs can occur, such as capillary leak syndrome, breathing
problems, serious infections, seizures, allergic reactions, and heart
problems among other possible complications (53).
Later on, Interferon alpha 2b (IFN-α 2b) was approved by
the FDA as a post-surgical adjuvant treatment. Previous studies
have shown that adjuvant treatment with IFN-α2b at intermedi-
ate doses for 2 years increased DFS of melanoma patients with
high risk of recurrence (stages IIb, IIC and III) in 10%, with no
significant effect on OS (54). IFN-α 2b is associated with severe
side effects. Based on the results of the EORTC 18991 trial, the FDA
approved PEG-interferon α-2b (PEG-IFN) (Sylatron) as adjuvant
therapy for high-risk melanoma. The median PFS of the PEG-IFN
group was significantly longer than the observation group, while
OS, a secondary endpoint, was not significantly different between
the two groups. One-third of the patients receiving PEG-IFN dis-
continued treatment because of toxicity. PEG-IFN is characterized
by a longer half-life and can be administered subcutaneously.
Much progress has been made in unraveling the mechanisms of
action of IFN’s anti-tumor activity. These include cell cycle inhibi-
tion by G1 arrest and anti-proliferative activity (55), the induction
of apoptosis (56–58), and the reduction of angiogenesis in some
tumors by reducing basic fibroblast growth factor (bFGF) and
vascular endothelial growth factor (VEGF) production (59, 60).
Several indirect immunomodulatory effects of interferon treat-
ment have been identified, including a role in T cell differentiation
and B cell development, which may aid in immune surveillance
by increasing Ag processing and upregulating MHC-I expression,
thus facilitating Ag recognition by cytotoxic CD8+ T cells. Besides,
IFN-α produces strong activation of monocytes and macrophages.
Activated macrophages produce reactive oxygen species and reac-
tive nitrogen intermediates, which have cytotoxic effects on target
cells (61). Additionally, activated monocytes produce cytokines
that initiate a Th1 response. More recently, IFN-α has been shown
to induce activation of NK-cells through the increase of NKG2D
and CD161 stimulatory signaling, thus enhancing NK-cell killing
of tumor cells (62, 63).
LIGHTS AND SHADOWS OF THERAPEUTIC APPROACHES FOR
MELANOMA TREATMENT
The phenomenon of oncogene-addicted tumors allowed the devel-
opment of targeted therapies with impressive clinical results
and, for the first time, rapid remissions in advanced metastatic
melanoma patients. These results supported the approval of tar-
geted therapies. However, targeted therapies are only useful for
patients whose tumors possess specific mutations. There can be
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serious related AEs, and the emergence of escape mechanisms and
drug-resistance may be difficult to overcome.
The unraveling of key immunomodulatory pathways involved
in anti-tumor immune responses has allowed the development
and approval of specific therapeutic approaches. For instance,
immune checkpoint-specific antagonist mAbs allow the achieve-
ment of long-lasting clinical responses in a small proportion of
advanced metastatic patients; these responses are often slow to
manifest and take several months to achieve (5). Furthermore,
there are concerning irAEs, primarily because these therapies
are directed toward targets that are also involved in physiolog-
ical processes. Additionally, specific biomarkers are needed to
implement these treatments in the patient populations that would
benefit the most.
Melanoma therapeutic vaccines have shown to be safe and
to preserve the quality of life of patients with cancer (64, 65).
Specific anti-tumor Ag responses have been demonstrated in
about half of vaccinated patients. A small number of patients
documented clinical OR (~8.5%) (66, 67). The most rational
application of therapeutic vaccines seems to be as an adju-
vant therapy aimed at the control of micro-metastatic dis-
semination. However, there is insufficient evidence supporting
melanoma vaccine efficacy, or any correlation between immune
responses and clinical objective responses. Most clinical studies
have tested these vaccines in metastatic patients, perhaps fore-
shadowing possible control in earlier stage melanoma recurrence.
Immune monitoring in the tumor microenvironment is diffi-
cult to assess and relevant immune effectors have not yet been
identified.
Long-term responses to cytokine therapies such as IL-2 and
IFN-α have been documented, though in very few patients, high-
lighting once again the intimate relationship between the immune
system and melanoma (52, 54). However, the impact of cytokine
therapy on patients’ OS has not been demonstrated and the
associated AEs remain a major problem. Additional research is
needed to discover appropriate markers that allow the iden-
tification of the patients that are most likely to respond to
these therapies.
The ORR of ACT is approximately 50% (51). Some CR have
been reported, suggesting that this strategy may be an attractive
alternative for some melanoma patients. However, this procedure
is expensive, only 30–40% of biopsy specimens yield satisfactory
T cell population recovery for TIL preparation, and the process is
laborious and time intensive (49). Furthermore, prior host condi-
tioning with chemotherapy is required to increase the response to
ACT. This conditioning is associated with serious AEs, including
opportunistic infections and the frequent induction of vitiligo and
uveitis, presumably due to autoimmunity (49).
The absence of an association between objective responses and
OS has been widely reported with immunotherapeutic drugs and
targeted therapies. Immunotherapies often produce an atypical
clinical response pattern that includes delayed initial increases in
tumor burden, which is associated with inflammation or immune
cell infiltration of the tumor lesions, followed by regression and
changes in disease progression kinetics (68). Altogether, these data
underscore the idea that cancer immunotherapies need alterna-
tive efficacy endpoints in addition to the traditional outcome
parameters used in oncology clinical trials.
IMMUNOTHERAPY AND ONCOGENE-TARGETED DRUGS: THE
POWER OF COMBINATION STRATEGIES
As we have seen, new melanoma treatments, including oncogene-
targeted therapies and immunotherapies, have been recently
approved. Due to their different modes of action and possible
interactions, a special interest has arisen in using combination
therapies to improve melanoma control. Targeted therapies can
achieve impressive and rapid tumor remissions, though these
results are shadowed by the emergence of resistance mecha-
nisms through selection in heterogeneous tumors, limiting clinical
response to a relatively short duration. In contrast, immunother-
apy can give rise to long-term melanoma control by eliciting active
immune effectors that may lead to curative responses, but in a
small, select group of patients.
Why combine oncogene-targeted therapies and immunother-
apy? There is increasing evidence that oncogenes play a role in
the modulation of the expression of immune regulatory genes
and therefore interfere with the immune microenvironment. We
will focus on BRAFV600 in melanoma, where there is the most
evidence. Initial reports showed that BRAFV600E CM cell lines
secreted immunosuppressive IL-10,VEGF, and IL-6 molecules and
suppressed IL-12 and TNF-α production by DC in vitro, and that
this could be reversed by MEK-inhibitors or specific siRNA for
BRAFV600E or STAT-3 (69). Human BRAFV600E CM cell lines also
induced the expression of IL-1α and IL-1β, which in turn induced
COX-2 and PD ligand expression in tumor-associated fibroblasts,
suppressing T cell function. Interestingly, IL-1α expression was
down-regulated in human tumor biopsies following vemurafenib
treatment (70).
Studies investigating the underlying mechanisms of action
describe an increase in CD4+, CD8+/Treg, and NK-cell num-
bers following PLX-4720 activity in BRAFV600E-driven murine
melanoma models, showing that host immunity greatly con-
tributes to inhibitor activity. Furthermore, the combination of
PLX-4720 and anti-CCL2 or agonistic anti-CD137 antibodies
improved anti-tumor responses (71). Regarding innate immu-
nity, NK-cells will play a critical role in the control of BRAFV600E
metastatic melanoma tumors treated with PLX-4720 through a
perforin-dependent pathway. In the context of IL-2, PLX-4720-
induced ERK1/2 phosphorylation, CD69 expression and IFN-
γ release post NKp30 ligation in human NK-cells. A corollary
from this work was that simultaneous inhibition by BRAF and
MEK might preclude the activation of BRAFWT NK-cells. A
low dose of IL-2 improved the anti-metastatic efficacy of PLX-
4720, supporting the combination of NK-cell stimulatory agents
with BRAF-inhibitors (72). With regards to adaptive immu-
nity, BRAFV600E inhibition reportedly increased the expression
of melanocyte differentiation Ags on CM cells and enhanced the
activation of Ag-specific T cells in vivo (73). Neither PLX-4720
nor PLX-4032 BRAFV600E specific inhibitors interfered with the
viability or the functionality of T cells, allowing the implemen-
tation of a combinatorial approach with immunotherapy (74).
Other works reported that BRAF-inhibitors induced a paradoxi-
cal MAPK-dependent functional activation of T cells (75). This
effect was dose-dependent on BMS-908662, a pan-RAF inhibitor
(with activity against B-RAFV600, B-RAFwt, A-RAF, and C-RAF),
and dose-independent on PLX-4720 inhibitor. The authors pro-
posed that the paradoxical ERK activation in BRAFwt cells may
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be a common event with ATP-competitive inhibitors of the BRAF
kinase domain and showed that MEK inhibition blocks this para-
doxical activation. Interestingly, the combination of BMS-908662
with a CTLA-4 blockade improved anti-tumor action. In patients,
reports indicated that BRAF-inhibitors induced tumor Ag expres-
sion and the infiltration of CD8+ and CD4+ T cells in metastases
shortly after the initiation of treatment, which was followed by
a reduction in tumor size. Progressing patients, however, showed
a decrease in TILs. These results further support combinatorial
strategies (76). Other analysis of tumor biopsies pre- and post-
treatment with combinatorial dabrafenib/trametinib treatment
showed a reduction of the immunosuppressive cytokines IL-6 and
IL-8. However, CD8+ tumor infiltration, along with PD-1, Tim-3,
and PD-L1 expression also increased following treatment, suggest-
ing that these oncogene-targeted therapies might be limited and
should be combined with immunotherapy to achieve long-term
responses (77).
There remains much to learn about how the exposure of differ-
ent classes of immune cells to vemurafenib modulates immune
system activity. Interestingly, two ongoing clinical studies are
currently analyzing the kinetics and effects of BRAF inhibition
with vemurafenib (960 mg BID) on the innate and adaptive
immune system in patients with unresectable melanoma express-
ing a BRAFV600 mutation (NCT01942993 and NCT01813214).
These studies will evaluate changes in the immune cellular sig-
nature in blood circulation, comparing the baseline to differ-
ent time points after the initiation of vemurafenib treatment
through immunofluorescence and flow cytometry on blood
samples. Additionally, the timeline of the vemurafenib-induced
increase in T cell infiltration of tumors will be established
through analysis of biopsies. As will other immune-related
parameters, such as the activation state of TILs, expression
of immune-inhibitory proteins (B7-H1/PD-L1, IDO, Arginase),
changes in endothelial homing receptor ligands and tumor-
associated chemokines, the presence of immune/inflammatory
expression patterns, the presence of tissue-specific destruction
and IFN-gamma upregulation, and in vitro determination of
tumor cell lysis in comparison to allogeneic tumor cells. These
studies will provide a systematic and valuable body of data
that will aid in understanding the immune modulation induced
by anti-BRAF therapy. And will help to develop more ratio-
nalized combination strategies with BRAF-targeted therapies
and immunotherapy.
CURRENTS AVENUES OF RESEARCH
In Table 1, we present a selected list of ongoing clinical studies that
are exploring different combination therapies involving oncogene-
targeted therapy with different immunotherapeutic approaches
(current as of November 2014, source Clinical trials.gov and
EMEA data base).
IMMUNE CHECKPOINT BLOCKADE AND ONCOGENE-TARGETED
THERAPIES
Expectations are high regarding immune checkpoint blockade and
oncogene-targeted combination therapy, largely because of their
individual success in the treatment of advanced melanoma per se,
but also due to previous studies that have described oncogene
modulation of the immune microenvironment. Several initial
phase I/II trials are being conducted to evaluate the safety, qual-
ity of life, and immune functional status changes, in order to
define an administration schedule and related biomarkers for fur-
ther clinical development. These trials usually exclude patients
with active autoimmune disease or known immune impairment;
for example, patients receiving systemic immunosuppression for
organ transplantation.
Surprisingly, a study with ipilimumab and vemurafenib in
metastatic BRAFV600 mutated CM patients had to be terminated
due to hepatic toxicities (NCT01400451) (78). Patients received
a running period of oral vemurafenib, and then concomitant
vemurafenib with intravenous ipilimumab. In both cohorts, most
patients developed grade 2/3 hepatic AEs, including elevation in
aminotransferase and total bilirubin levels. The AEs were asymp-
tomatic and reversible with either temporary drug discontinuation
or administration of glucocorticoids. A similar study terminated
because of serious AEs was the combination of vemurafenib,
ipilimumab, and DNE3 (a PI3K–AKT inhibitor) in advanced
melanoma patients (NCT02095652). In order to analyze the
underlying mechanisms of targeted therapy-related toxicities, an
observational study is being conducted in patients with advanced
solid tumors treated with standard palliative targeted thera-
pies (NCT01758575). Monotherapies include antiangiogenic RTK
inhibitors, EGFR inhibitors, mTOR inhibitors, BRAF-inhibitors,
and ipilimumab. The study will investigate toxicity both at the
systemic and local tissue level.
In spite of these reported toxicities, protocols designed with
other drug combinations are currently being conducted. A phase
II study assessing a sequential design that combines vemurafenib
followed by ipilimumab has completed patient recruitment and
results are expected for 2015 (NCT01673854). A new phase I/II
trial studying concurrent treatment with dabrafenib and ipili-
mumab is ongoing (NCT02200562). Another phase I trial is assess-
ing the co-administration of the BMS-908662 pan-RAF inhibitor
and ipilimumab (NCT01245556). A combination of ipilimumab,
dabrafenib,and trametinib is being assessed in advanced BRAFV600
CM patients. One such study is a four-arm, randomized trial
with a sequential design that initiated treatment with dabrafenib
and/or trametinib followed by ipilimumab (NCT01940809). Yet
another open trial is testing a concomitant schedule; a doublet
arm in which patients receive a running cycle of dabrafenib fol-
lowed by co-administration with ipilimumab, and a triplet arm
where patients receive dabrafenib, trametinib, and ipilimumab
(NCT01767454).
An interesting option for c-KIT mutated melanoma and GIST
patients is a dose escalation schedule with cycles of imatinib
followed by ipilimumab, currently underway (NCT01738139).
Regarding the PD-1–PD-L1 axis, pembrolizumab plus dabrafenib
and Trametinib concomitant administration is being assessed in
advanced melanoma patients. This study replaces pembolizumab
with a placebo and conducts dabrafenib and trametinib monother-
apy arms (NCT02130466). When nivolumab and ipilimumab are
co-administered there are discernable induction and maintenance
phases. Furthermore, MEDI4736 (PD-L1) in combination with
oncogene-targeted therapies is being studied in advanced patients
(NCT02027961). Patients with BRAFV600E/K tumors will receive
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Table 1 | Ongoing clinical studies combining immunotherapy and oncogene-targeted therapy.
Trial identifier
(status)
Combination
therapy
Patient
condition
Study
phase
Sponsor Study title Study design
1. IMMUNE CHECKPOINT BLOCKADE
NCT01940809
(recruiting)
Dabrafenib;
ipilimumab;
trametinib
Stage IV
melanoma or
unresectable;
Stage III
melanoma
I National
Cancer
Institute (NCI)
A Sequential Safety and
Biomarker Study of
BRAF-MEK Inhibition on
the Immune Response
in the Context of
CTLA-4 Blockade for
BRAF Mutant
Melanoma
Arm A (ipilimumab, dabrafenib, trametinib): Patients
receive dabrafenib PO BID and trametinib PO QD for
25 days. Patients then receive ipilimumab IV over 90 min.
Treatment with ipilimumab repeats every 3 weeks for four
courses in the absence of disease progression or
unacceptable toxicity.
Arm B (ipilimumab, trametinib): Patients receive
trametinib PO QD for 25 days. Patients then receive
ipilimumab IV over 90 min. Treatment with ipilimumab
repeats every 3 weeks for four courses in the absence of
disease progression or unacceptable toxicity.
Arm C (ipilimumab, dabrafenib): Patients receive
dabrafenib PO BID for 25 days. Patients then receive
ipilimumab IV over 90 min. Treatment with ipilimumab
repeats every 3 weeks for four courses in the absence of
disease progression or unacceptable toxicity.
Arm D (ipilimumab): Patients receive ipilimumab IV over
90 min. Treatment repeats every 3 weeks for four courses
in the absence of disease progression or unacceptable
toxicity.
Other: laboratory biomarker analysis.
NCT01767454
(recruiting)
Dabrafenib;
trametinib;
ipilimumab
Solid tumors I GlaxoSmithKline Phase 1 Study of the
BRAF-Inhibitor
Dabrafenib±MEK
Inhibitor Trametinib in
Combination With
Ipilimumab for V600E/K
Mutation-Positive
Metastatic or
Unresectable
Melanoma
Doublet arm: Cohort A1 dabrafenib (150 mg orally BID) for
2 weeks+ ipilimumab.
Cohort A-2 dabrafenib (100 mg orally BID) for
2 weeks+ ipilimumab (3 mg/kg Q3W, four infusions) over
12–16 weeks.
Dabrafenib will be continued through combination with
ipilimumab and post-ipilimumab phases, until no longer of
clinical benefit, unacceptable toxicity or death.
Triplet arm
Initiated using dabrafenib and ipilimumab doses
established in the doublet dose-finding study. Dabrafenib
and trametinib are taken orally for 2 weeks followed by
ipilimumab 3 mg/kg Q3W (four total infusions over
12–16 weeks).
Cohort B-1: dabrafenib 100 mg BID+ trametinib 1 mg once
daily+ ipilimumab.
Cohort B2: dabrafenib 150 mg BID+ trametinib 1 mg once
daily+ ipilimumab.
Cohort B3: dabrafenib 150 mg BID+ trametinib 2 mg once
daily+ ipilimumab.
Dabrafenib and trametinib will be continued through
combination with ipilimumab and post-ipilimumab phases
until no longer of clinical benefit, unacceptable toxicity or
death.
NCT01673854
(not recruiting)
Ipilimumab;
vemurafenib
Previously
untreated,
metastatic
melanoma with
activating
BRAFV600
mutation
II Bristol-Myers
Squibb
A Single Arm
Open-Label Phase II
Study of Vemurafenib
Followed by Ipilimumab
in Subjects With
Previously Untreated
V600 BRAF Mutated
Advanced Melanoma
Vemurafenib followed by Ipilimumab.
Vem 1 Phase: vemurafenib 960 mg orally twice daily for
6 weeks followed by ipilimumab 10 mg/kg intravenous
injection once every 3 weeks for four doses, then once
every 12 weeks starting at week 24 until disease
progression (PD) or unacceptable toxicity (for a maximum
treatment period of 3 years from the first dose).
Vem 2 Phase: vemurafenib re-started at time of PD,
unacceptable toxicity on ipilimumab until PD or
unacceptable toxicity.
(Continued)
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Table 1 | Continued
Trial identifier
(status)
Combination
therapy
Patient
condition
Study
phase
Sponsor Study title Study design
NCT02200562
(not yet
recruiting)
Ipilimumab;
dabrafenib
Stage III or IV,
BRAFV600E/K/R
positive
Melanoma
I/II University of
Utah
Ipilimumab and
Dabrafenib in the 1st
Line Tx of Unresectable
Stage III/IV Melanoma
Experimental: concurrent ipilimumab and dabrafenib as
first line treatment in Stage III or IV melanoma.
NCT01738139
(recruiting)
Imatinib mesylate;
ipilimumab
Advanced
cancers: KIT
confirmed GIST,
melanoma, and
uncategorized
solid tumors
I M.D. Anderson
Cancer Center
A Phase I Trial of
Ipilimumab
(Immunotherapy) and
Imatinib Mesylate (c-Kit
Inhibitor) in Patients
With Advanced
Malignancies
Ipilimumab+ Imatinib Mesylate
Dose escalation: initial daily oral administration of imatinib
mesylate (400 mg) for 14 days. A single ipilimumab
treatment (1 mg/kg) given on day 15 will be added to daily
to imatinib mesylate therapy. The dose escalation group’s
first study cycle is 35 days. Each cycle after that is
21 days.
Expansion cohort: using the MTD determined by the
dose escalation study to treat patients with KIT confirmed
GIST, melanoma, and uncategorized solid tumors.
Both studies will consist of a screening visit and
continuous 21-day treatment cycles. Cycles will be
repeated every 21 days for four cycles until disease
progression or development of intolerable toxicities,
followed by a post-treatment visit.
NCT02224781
(not yet
recruiting)
Nivolumab;
ipilimumab;
dabrafenib;
trametinib
Recurrent
BRAFV600
Mutant
Melanoma;
Stages IIIA, IIIB,
IIIC and IV
III National
Cancer
Institute (NCI)
A Randomized Phase III
Trial of Dabrafenib+
Trametinib Followed by
Ipilimumab+
Nivolumab at
Progression vs.
Ipilimumab+
Nivolumab Followed by
Dabrafenib+
Trametinib at
Progression in Patients
With Advanced
BRAFV600 Mutant
Melanoma
Arm A (immunotherapy): IMMUNOTHERAPY
INDUCTION (COURSES 1–2): Patients receive nivolumab
IV over 60 min and ipilimumab IV over 90 min on days 1 and
22. Treatment repeats every 6 weeks for two courses in
the absence of disease progression or unacceptable
toxicity.
IMMUNOTHERAPY MAINTENANCE (COURSES 3–14):
Patients receive nivolumab IV over 60 min on days 1, 15,
and 29. Treatment repeats every 6 weeks for up to 12
courses in the absence of disease progression or
unacceptable toxicity. Upon disease progression, patients
cross over to Arm C.
Arm B (BRAF-inhibitor therapy): Patients receive
dabrafenib PO BID and trametinib PO daily on days 1–42.
Courses repeat every 6 weeks in the absence of disease
progression or unacceptable toxicity. Upon disease
progression, patients cross over to Arm D.
Arm C (BRAF-inhibitor therapy): Patients receive
dabrafenib PO BID and trametinib PO daily on days 1–42.
Courses repeat every 6 weeks in the absence of disease
progression or unacceptable toxicity.
Arm D (immunotherapy): IMMUNOTHERAPY
INDUCTION (COURSES 1–2): Patients receive nivolumab
IV over 60 min and ipilimumab IV over 90 min on days 1 and
22. Treatment repeats every 6 weeks for two courses in
the absence of disease progression or unacceptable
toxicity.
IMMUNOTHERAPY MAINTENANCE (COURSES 3–14):
Patients receive nivolumab IV over 60 min on days 1, 15,
and 29. Treatment repeats every 6 weeks for up to 12
courses in the absence of disease progression or
unacceptable toxicity.
Other: laboratory biomarker analysis, quality-of-life
assessment.
(Continued)
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Table 1 | Continued
Trial identifier
(status)
Combination
therapy
Patient
condition
Study
phase
Sponsor Study title Study design
NCT02027961
(recruiting)
Anti-PD-L1 Mab
(MEDI4736);
dabrafenib;
trametinib
Unresectable
Stage IIIc or
Stage IV
melanoma
I MedImmune
LLC
A Phase 1 Open-label
Study of Safety and
Tolerability of MEDI4736
in Subjects With
Metastatic or
Unresectable
Melanoma in
Combination With
Dabrafenib and
Trametinib or With
Trametinib Alone
Cohort A (BRAF V600E or V600K mutation-positive):
Dabrafenib/Trametinib/MEDI4736.
Cohort B (BRAF mutation-negative)Trametinib/MEDI4736.
Cohort C (BRAF mutation-negative):
Trametinib/MEDI4736.
Study evaluation will include maximum tolerated dose,
safety, anti-tumor activity, pharmacokinetic, and
immunogenicity of MEDI4736.
NCT02130466
(recruiting)
Pembrolizumab;
dabrafenib;
trametinib
Advanced
melanoma
(unresectable
Stage III) or
metastatic
(Stage IV)
excluding uveal,
mucosal, or
ocular melanoma
I/II Merck Sharp &
Dohme Corp.
in collaboration
with Glaxo
Wellcome
A Phase I/II Study to
Assess the Safety and
Efficacy of MK-3475 in
combination with
Trametinib and
Dabrafenib in subjects
with advanced
melanoma
Pembrolizumab + Dabrafenib +Trametinib (Parts 1, 2,
and 3)
Pembrolizumab intravenously (IV) on Days 1 and 22, or on
Days 1, 15, and 29 of each 6-week cycle; dabrafenib
capsules, 150 mg/day total, orally, in a divided dose (twice
per day, or BID) starting on Day 1, through study treatment
discontinuation; trametinib tablets, 2 mg, orally, once daily
(QD) starting on Day 1, through study treatment
discontinuation.
Placebo Comparator: Placebo + Dabrafenib +Trametinib
(Part 3)
Placebo IV on Days 1 and 22, or on Days 1, 15, and 29 of
each 6-week cycle; dabrafenib capsules, 150 mg/day total,
orally, in a divided dose BID starting on Day 1, through
study treatment discontinuation; and trametinib tablets,
2 mg, orally, QD starting on Day 1, through study treatment
discontinuation.
Pembrolizumab +Trametinib (Parts 1 and 2)
Pembrolizumab IV on Days 1 and 22, or on Days 1, 15, and
29 of each 6-week cycle and trametinib tablets, 2 mg,
orally, QD starting on Day 1, through study treatment
discontinuation.
Pembrolizumab + Dabrafenib (Parts 1 and 2)
Pembrolizumab IV on Days 1 and 22, or on Days 1, 15, and
29 of each 6-week cycle and dabrafenib capsules,
150 mg/day total, orally, in a divided dose BID starting on
Day 1, through study treatment discontinuation.
NCT01245556
(completed)
BMS-908662
ipilimumab
Unresectable
stage III or
metastatic
melanoma with
V600E mutation
I Bristol-Myers
Squibb
A Phase 1 Study of a
RAF inhibitor
(BMS-908662)
administered in
combination with
immunotherapy
(ipilimumab) in subjects
with unresectable
Stage III or Stage IV
melanoma
Experimental: BMS-908662 or Ipilimumab (A):
BMS-908662, oral, escalating doses starting at 25 mg,
Q12h daily, continuously. Ipilimumab, IV, escalating doses
starting at 3 mg/kg. Once every 3 weeks for 6 weeks, then
once every 12 weeks, continuously.
Experimental: BMS-908662 or Ipilimumab (B):
BMS-908662, oral, escalating doses starting at 25 mg
Q12h daily for 3 weeks with 3 weeks interval for four
cycles, then Q12h daily for 3 weeks every 12 weeks,
continuously. Ipilimumab, IV, escalating doses starting at
3 mg/kg, Once every 6 weeks for four cycles, then once
every 12 weeks, continuously.
(Continued)
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Table 1 | Continued
Trial identifier
(status)
Combination
therapy
Patient
condition
Study
phase
Sponsor Study title Study design
2. VACCINES
NCT01876212
(recruiting)
Dasatinib;
DC vaccine
Metastatic
melanoma
I Hussein Tawbi,
University of
Pittsburgh
A randomized Phase 2
Pilot Study of Type
I-polarized autologous
dendritic cell vaccines
incorporating tumor
blood vessel antigen
(TBVA)-derived peptides
in combination with
dasatinib in patients
with metastatic
melanoma
Arm A: vaccine (107 cells, i.d.) prior dasatinib (orally, 70 mg
2 × day).
Arm B: vaccine (107 cells, i.d.) concomitant dasatinib
(orally, 70 mg 2 × day).
Vaccine i.d administration will be in the vicinity of the four
nodal drainage groups of the four extremities.
NCT02077114
(completed
9/25/2014)
Vaccine-peptide
derived from the
protein IDO (IDO
Long); ipilimumab;
vemurafenib
Malignant
melanoma with
metastasis
I Herlev Hospital Peptide vaccination in
combination with either
ipilimumab or
vemurafenib for the
treatment of patients
with unresectable
Stage III or IV malignant
melanoma A Phase I
study (first in man)
Experimental: Ipilimumab
Patients who are candidates for treatment with Ipilimumab
according to standard criteria.
Experimental:Vemurafenib
Patients are candidates for treatment with Vemurafenib
who according to standard criteria.
Vaccine consisting of a peptide derived from the protein
IDO.
All patients will receive seven vaccines containing IDO
long.
3. OTHER IMMUNOTHERAPIES
NCT01754376
(recruiting)
Vemurafenib;
aldesleukin
Metastatic or
unresectable
melanoma with
V600E mutation
II Massachusetts
General
Hospital
COMBAT 1: A Phase II
trial of combined
BRAF-targeted therapy
and immunotherapy for
melanoma
Treatment arm: Oral vemurafenib twice a day plus i.v
infusion of aldesleukin. Vemurafenib twice a day for
2 weeks followed by one course of aldesleukin via IV
infusion on Day 15 (aldesleukin via IV infusion every 8 h for
the first 5 days (week 1); one course of aldesleukin is
12 weeks long. During days 29–33 one more week of
aldesleukin (Week 2).
Oral vemurafenib twice daily will continue during the
course of aldesleukin.
NCT01683188
(recruiting)
Vemurafenib; HD
IL-2 (Proleukin)
Metastatic
melanoma
IV Prometheus
Laboratories
A Multi-Center Study of
High-Dose Aldesleukin
(Interleukin-2)+
Vemurafenib therapy in
patients with
BRAFV600
mutation-positive
metastatic melanoma
Cohort 1: Patients who have received fewer than 7 weeks
vemurafenib dosing prior to treatment with HD IL-2.
Drug: vemurafenib+HD IL-2
Cohort 2: Patients who have receive >7–18 weeks
vemurafenib dosing prior to treatment with HD IL-2.
NCT01959633
(recruiting)
Vemurafenib;
Peg-interferon
Unreseactable
stage IIIb-IV
metastatic
melanoma, V600
BRAF mutations
positive
I/II Fondazione
Melanoma
Onlus
Phase I-II study of the
combination
vemurafenib plus
PEG-interferon in
advanced melanoma
patients harboring the
V600BRAF mutation
Vemurafenib 960 mg BID+Peg-interferon 1/2/3µg/kg once
weekly.
Phase I: Cohort (1) Peg-interferon 1µg/kg once per week
s.c. Cohort (2) Peg-interferon 2µg/kg once per week s.c.
Cohort (3) Peg-interferon 3µg/kg once per week s.c.
Interferon treatment should start after 15 days of
vemurafenib only.
Phase II: Is included the cohort selected by phase I due to
MTD and expanded at RD.
Objectives: verify if the combination vemurafenib plus
PEG-interferon in advanced melanoma patients harboring
the BRAFV600 mutation is more active than vemurafenib
and to verify the upregulation of IFNAR1 expression in
patients treated with the combination vemurafenib plus
PEG-interferon.
(Continued)
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Table 1 | Continued
Trial identifier
(status)
Combination
therapy
Patient
condition
Study
phase
Sponsor Study title Study design
NCT01585415
(active not yet
recruiting)
Vemurafenib;
young TIL;
cyclophos-
phamide;
fludarabine;
aldesleukin
Metastatic
Cancer;
Melanoma
I National
Cancer
Institute (NCI)
A Pilot Trial of the
Combination of
Vemurafenib With
Adoptive Cell Therapy in
Patients With
Metastatic Melanoma
Patients will undergo biopsy or resection to obtain tumor
for generation of autologous TIL cultures.
When cryopreserved TIL are available patients will begin
the administration of Vemurafenib 960 mg (day 1) twice
daily until the disease progresses or patients are taken off
protocol.
On day 7, patients will begin a non-myeloablative
lymphocyte depleting preparative regimen of
cyclophosphamide (60 mg/kg/day IV) on days 7 and 6 and
Fludarabine (25 mg/m2/day IV) on days 5 through 1.
On day 0, patients will receive between 1×109 and
2×1011 young TIL and then begin high-dose aldesleukin
(720,000 IU/kg IV every 8 hours for up to 15 doses).
Clinical and immunologic responses will be evaluated
about 4-6 weeks after the last dose of aldesleukin.
NCT01659151
(recruiting)
Vemurafenib;
HD IL-2;
ACT with TIL
infusion;
lymphodepletion
(fluradabine and
cyclophos-
phamide)
Metastatic
melanoma
II H. Lee Moffitt
Cancer Center
and Research
Institute
A Phase II clinical trial of
vemurafenib with
lymphodepletion plus
adoptive cell transfer
and high-dose IL-2 in
patients with metastatic
melanoma
Lymphodepletion regimen with fludarabine and
cyclophosphamide will be given before TILs infusion.
ACT with TIL infusion: TILs obtained from surgically
removed tumors will be amplified ex vivo and then given
back to the patient by i.v. infusion.
A high-dose regimen of IL-2 will be given after participants
receive the infusion of the T cells.
Vemurafenib will be given for about 3 weeks while T cells
are being grown in the lab and then again after T cell
infusion for up to 2 years.
NCT01758575
(recruiting)
Sunitinib;
sorafenib;
pazopanib;
cetuximab;
panitumunab;
everolimus;
vemurafenib;
ipilimumab
Advanced or
metastatic solid
tumors
Obser-
vational
VU University
Medical Center
Clinical evaluation of the
underlying mechanisms
of targeted
therapy-related
toxicities
Antiangiogenic tyrosine kinase inhibitors
Sunitinib: 50 mg orally, daily. Sorafenib: 400 mg orally, twice
daily Pazopanib: 800 mg orally, daily.
EGFR inhibitors
Cetuximab 250 mg/m2 intravenously, weekly.
Panitumumab 6 mg/kg intravenously, every 2 weeks.
mTOR inhibitors
Everolimus 10 mg orally, daily.
BRAF-inhibitor
Vemurafenib 960 mg orally, twice daily.
Anti-CTLA-4 antibody
Ipilimumab 3 mg/kg intravenously, every 3 weeks.
dabrafenib, trametinib, and MEDI4736 combination therapy.
Patients with BRAF mutation-negative tumors will only receive
trametinib plus MEDI4736. A randomized trial in BRAFV600 stage
III–IV melanoma patients is being conducted with multi-therapy
combination (NCT02224781). The trial compares a group treated
with dabrafenib plus trametinib followed by ipilimumab plus
nivolumab in the case of progression, to a group treated with
ipilimumab plus nivolumab followed by dabrafenib plus tram-
etinib at progression. The primary outcome focuses on OS; the
secondary outcome on PFS and toxicities. Additional outcomes
include genetic characteristics and symptom burden.
VACCINES AND ONCOGENE-TARGETED THERAPIES
Besides inhibiting target kinases in cancer cells, dasatinib also
inhibits a wide variety of kinases, such as src, tec, syk, and
gck-families, which are essential for immune system function
(79). Chronic myeloid leukemia patients have an increased pro-
portion of granzyme B-expressing T cells at diagnosis, which is
further increased by dasatinib therapy. Furthermore, dasatinib-
treated CML patients have a higher proportion of effector CD4+
T cells that differentiate into Th1-type cytokine producers and
are capable of producing IFN-γ, which is key for tumor control
(80). Interestingly, although reports have indicated that dasatinib
inhibits T cell activation via a blockade of lymphocyte-specific
protein tyrosine kinase (Lck)-mediated proximal T cell recep-
tor signaling in vitro (81), when administered in vivo dasatinib
can profoundly enhance T effector cell activation, expansion, and
function (82). In preclinical models, Yang et al. have recently
reported that dasatinib treatment in BALB/c mice bearing P815
mastocytomas improved the recruitment of T cells into the tumor
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and surrounding stroma, an immunological response required to
achieve the clinical benefits associated with therapeutic vaccines
(83). Thus, a combinatorial protocol was tested in mice bear-
ing established sub-cutaneous M05 (B16.OVA) melanoma. This
protocol used specific vaccination with an OVA-peptide loaded
DC-vaccine to activate and expand tumoricidal CD8+ T cells plus
systemic administration of dasatinib to facilitate the refined tar-
geting of vaccine-induced effector T cells to the tumor microenvi-
ronment. This approach provided a superior anti-tumor response
to either single-agent modality alone. The increased efficacy of
the combinatorial treatment included a reduction in the hypoxic-
signaling associated with reduced levels of immunosuppressive
CD11b+Gr1+ myeloid-derived suppressor cells and Treg popula-
tions in the melanoma microenvironment. Furthermore, dasatinib
in combination with the DC-vaccine upregulated Type-1 T cell-
recruiting CXCR3-ligand chemokines in the tumor stroma, which
correlated with the activation and recruitment of Type-1, vaccine-
induced CXCR3+CD8+ TILs and CD11c+ DC into the tumor.
This combinatorial approach resulted in a profound “spreading”
of the repertoire of melanoma-associated Ags recognized by CD8+
TILs (82). This evidence provided the rationale for a phase I
clinical study of dasatinib in combination with a DC-cell based
vaccine loaded with tumor blood vessel Ag (TBVA) in metastatic
melanoma patients, which is currently ongoing (NCT01876212).
A newly discovered tumor cell escape mechanism is through
the upregulation of the tryptophan-catabolizing enzyme known
as IDO. Tryptophan is essential for the function of T cells; hence,
the depletion of Trp leads to T cell anergy and apoptosis (84).
IDO upregulation leads to cancer progression by suppressing T
cell immunity, thereby elucidating IDO as a novel potential target
for anticancer therapy. The IDO pathway is linked to Treg biol-
ogy, since IDO-expressing DCs induce the differentiation of naïve
CD4+ cells toward a FoxP3+ phenotype (84). Cancer patients
possess spontaneous IDO-peptide specific T cells that are able to
recognize and kill both IDO positive tumor cells and DCs (85).
Targeting IDO is being explored in clinical trials for patients with
metastatic solid tumors using IDO inhibitors such as DMT-1 and
INCB024360 or IDO-peptide vaccines. The vaccine combinato-
rial approach may induce long-lasting IDO-specific memory T
cells that could re-activate and be recruited to the tumor site when
needed. Targeting IDO by a synthetic peptide vaccine [IDOlong;
IDO (194–214) peptide sequence: DTLLKALLEIASCLEKALQVF]
in combination with ipilimumab or vemurafenib was tested in a
recently completed phase I clinical study for metastatic melanoma
patients (NCT02077114). The study results have not yet been pub-
lished, but will evaluate safety and tolerability as well as immune
response. Reactivity to epitopes nested within the sequence of the
peptide used for vaccination will be assessed in T cells from periph-
eral blood at different times. Reactivity will be assessed using
ELISPOT (IFN-γ and TNF-α) and fluorochrome-conjugated HLA
tetramers to enumerate the frequency of CD8+ T cell specific
precursors for epitopes within the peptide sequence.
OTHER IMMUNOTHERAPIES AND ONCOGENE-TARGETED THERAPIES
IL-2 is an immunotherapy drug that increases the proliferation
of the T lymphocytes and NK-cells responsible for targeting
and eliminating cancer cells. Unfortunately, this elimination is
accompanied by high toxicity, since IL-2 is used in high-dose reg-
imen. As previously mentioned, targeting of mutated BRAFV600E
with vemurafenib increases Ag expression on the surface of
melanoma cells, which can make them easier targets for cyto-
toxic T lymphocytes and NK-cells. This suggests that combining
BRAF-targeted therapy with IL-2 could contribute to increased
tumor destruction. This hypothesis is being tested in a phase II
clinical study (NCT01754376). The study design consists in pri-
mary treatment with oral vemurafenib BID for 2 weeks followed
by one course of aldesleukin intravenous infusion (12 weeks long).
Patients will also receive vemurafenib twice daily during the course
of aldesleukin. Since this is a single arm study the efficacy of the
vemurafenib/aldesleukin combination, measured by PFS, will be
evaluated in comparison to an historic control of vemurafenib
alone. The study will assess response rate, OS, safety, and toxic-
ity. Preclinical data indicating that pharmacologic inhibition of
mutated BRAF enhance the immunogenicity of melanoma with-
out adversely affecting the cellular immune response will also
be assessed. The study will explore biomarkers that may be rel-
evant to predicting patient responsiveness to vemurafenib and
aldesleukin, explaining primary or acquired resistance to vemu-
rafenib, indicating the pharmacodynamic effects of vemurafenib
and monitoring the disease. Another open-label, uncontrolled,
two-arm, multi-center study has been designed to assess CR rate
in BRAFV600 metastatic melanoma patients who have received
vemurafenib plus HD IL-2 (NCT01683188). Patients will initially
receive treatment with vemurafenib interspersed with two courses
of HD IL-2. Eligible patients have been on vemurafenib therapy
for 0–18 weeks, those patients previously taking vemurafenib must
have responding or stable disease and all must meet the require-
ments for HD IL-2 dosing. Two cohorts will be enrolled, differing
only in how they are characterized prior to HD IL-2 treatment:
Cohort 1, patients naïve to vemurafenib and HD IL-2 therapy;
Cohort 2, patients who have been on vemurafenib therapy for>7–
18 weeks with stable or responding disease before starting HD IL-2.
Patients in both cohorts will discontinue vemurafenib prior to each
treatment with HD IL-2 and resume dosing after each discharge.
Patients will receive up to two courses (four cycles) of HD IL-2.
IFN-α acts via engagement of a Type I IFN receptor consist-
ing of two subunits (IFNAR1 and IFNAR2) followed by signaling
through the JAK and the STAT family to activate the transcrip-
tion of IFN-stimulated genes [reviewed in Ref. (58)]. A phase
I/II trial has been launched to test this combination in advanced
melanoma patients. This study is designed to evaluate the safety
and the efficacy of the vemurafenib/PEG–interferon combination
as well as the IFNAR1 upregulation induced by this treatment. Pre-
vious preclinical work reported by Kumar et al. demonstrated in a
BRAFV600E melanoma cell line that oncogenic BRAF–MAPK sig-
naling leads to the acceleration of IFNAR1 degradation by induc-
ing βTrcp2 expression (86). Pharmacologic inhibition of either
RAF or MEK1 stabilized IFNAR1 in melanoma cells and decreased
their tumorigenicity. The destabilization and downregulation of
IFNAR1 in BRAFV600E melanomas might account for the subop-
timal anti-proliferative effects of IFN. Preclinical results obtained
in murine models suggest that a combination treatment of IFN-α
with RAF or MAPK inhibitors could decrease BRAF signaling and
βTrcp2 expression and should prevent the rapid degradation of
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IFNAR1. This increase in the extent of IFN-α signaling could pro-
vide a promising strategy for treatment of melanoma. However,
in vitro results also suggests that the BRAF-inhibitor BAY 43-9006
(Sorafenib) may decrease the extent of direct anti-proliferative
responses to IFN-α by directly inhibiting the catalytic activity of
JAK (86).
As previously mentioned, another immunotherapeutic strategy
for the treatment of metastatic melanoma is ACT, with autolo-
gous TIL infusion after a lymphodepleting regimen, combined
with IL-2 administration to support TIL growth. Furthermore,
PLX-4720 significantly increased tumor infiltration by adoptively
transferred T cells in vivo and enhanced the anti-tumor activity
of ACT in a xenograft model with labeled T cells and human CM
cell lines (87). This increase in tumor infiltration was primarily
an effect of the inhibition of VEGF secretion by tumor cells. Cur-
rently, two open clinical studies are testing the combination of
vemurafenib with ACT patients in BRAFV600 melanoma. In the
study NCT01585415, the safety of vemurafenib administration
will be evaluated both before and concurrent to autologous TIL
infusion along with high HD-IL2, following a non-myeloablative
lymphodepleting preparative regimen with Fluradabine. Further-
more, this study may provide information on how this combina-
tion of therapies mediates clinical tumor regression in patients, as
well as the immunologic impact of BRAFV600E inhibition on the
lymphoid infiltrate in melanoma deposits. In another study, the
efficacy and side effects of this combination will also be analyzed
(NCT01659151). This combination of therapies is designed to
take advantage of the vemurafenib-induced upregulation of tar-
get Ags before TIL infusion. Furthermore, BRAF inhibition could
contribute to the “autovaccination” of patients as tumor destruc-
tion leads to epitope exposition and immune effector elicitation.
However, some questions will remain unanswered, since treat-
ment with vemurafenib before harvesting the tumor for use in
TIL could contribute to an increase in T cell infiltrate in the
melanoma lesions. This could enrich TIL samples and potentially
improve ACT outcome. These studies may elucidate whether the
pre-ACT lymphodepleting regimen, necessary for ACT success,
impairs vemurafenib treatment. Knight et al. have suggested that
this may be the case if vemurafenib anti-tumor activity is mediated
by resident immune cells (71). Thus, further research is necessary
to assess the timing of TIL recovery, the lymphodepletion regimen
and vemurafenib administration.
FUTURE DIRECTIONS AND PERSPECTIVES
Combination therapies comprised of oncogene-targeted and
immunotherapeutic strategies are a promising, emerging
approach to melanoma treatment. Oncogenes impact not only
tumor proliferation, but also other cancer hallmarks such
as immune system evasion, which favors a tumor-permissive
immune microenvironment. There is increasing evidence that
oncogene-targeted inhibitors not only induce tumor cell death, but
can also contribute to the restoration of an anti-tumor immune
microenvironment. Oncogene-targeted therapies offer the possi-
bility of rapid bulky tumor elimination, generate a vaccine-like
boost and Ag tumor spreading and favor tumor infiltration by
immune effectors, all of which may contribute to more extensive
and durable tumor control.
Disease stage is a significant consideration in the design of com-
bination strategies. In advanced metastatic melanoma, response
kinetics has been a key factor in agent selection. Patients who
have rapidly progressing tumors with druggable mutations can
benefit from oncogene-targeted drugs first, allowing the elimi-
nation of important tumor masses in a short time. Sequential
immunotherapy administration could cause tumor immune infil-
tration and therefore, promote durable immune control of disease
dissemination. Concomitant administration of oncogene-targeted
therapies with immunotherapy has produced serious AEs, though
results are pending from additional clinical studies. Advanced
patients with stable or slowly progressing disease might benefit
from immunotherapies that act gradually but achieve long-lasting
responses. Recent results with the antagonist mAb pembrolizumab
are encouraging for patients who move on to immunotherapy or
oncogene-targeted therapies. Instead, in the adjuvant setting, can-
cer vaccines could be the first choice to elicit a robust immune
response. Their combination with an immune checkpoint block-
ade could enhance and prolong immune stimulation and effector
numbers.
The choice of the best therapeutic design for combining
immunotherapy with oncogene-targeted drugs (sequential vs.
concurrent schemes), avoidance of toxicity and induction of
long-lasting clinical responses are controversial and challeng-
ing issues. There is an urgent need for biomarker development
through histologic and genomic analysis of the tumor and its
microenvironment. Biomarkers will be able to predict which
patients are likely to have a clinical benefit and which will have
severe AEs. The use of biomarkers will give rise to a more
personalized medicine for cancer treatment.
The development of more effective melanoma treatments based
on oncogene-targeted therapy in combination with immunother-
apy can emerge from novel hypothesis-testing and biomarker-
driven clinical trials designed to optimize both drug dosing and
immunotherapy scheduling. Ongoing and future clinical studies
will certainly contribute to this future and illuminate these new
roads for melanoma therapy.
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